| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 88 |
| 1 | ATEZOLIZUMAB | 70 |
| 2 | RIVAROXABAN | 61 |
| 3 | RIBAVIRIN | 45 |
| 4 | FUROSEMIDE | 34 |
| 5 | SOFOSBUVIR | 34 |
| 6 | SPIRONOLACTONE | 30 |
| 7 | APIXABAN | 29 |
| 8 | ASPIRIN | 28 |
| 9 | ASPIRIN 325 MG | 23 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ATEZOLIZUMAB | 70 | 0.0018 |
| 1 | SOFOSBUVIR | 34 | 0.0017 |
| 2 | NEVIRAPINE | 15 | 0.0017 |
| 3 | ADEFOVIR DIPIVOXIL | 2 | 0.0016 |
| 4 | CHLORZOXAZONE | 2 | 0.0015 |
| 5 | POLIDOCANOL | 2 | 0.0013 |
| 6 | NELFINAVIR MESYLATE | 2 | 0.0010 |
| 7 | TREMELIMUMAB | 4 | 0.0009 |
| 8 | MARAVIROC | 2 | 0.0009 |
| 9 | IVABRADINE | 6 | 0.0009 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Sclerosing Agent [EPC] | 2 | 0.0044 |
| 1 | 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor [EPC] | 1 | 0.0012 |
| 2 | CCR5 Co-receptor Antagonist [EPC] | 2 | 0.0009 |
| 3 | Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC] | 39 | 0.0007 |
| 4 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 15 | 0.0006 |
| 5 | Thyroid Hormone Synthesis Inhibitor [EPC] | 6 | 0.0006 |
| 6 | Nucleoside Analog Antiviral [EPC] | 45 | 0.0005 |
| 7 | Phosphodiesterase 3 Inhibitor [EPC] | 3 | 0.0005 |
| 8 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 88 | 0.0005 |
| 9 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 2 | 0.0003 |